

1 **Title**

2 **Pilot implementation of short message service for randomisation in a multisite pragmatic**
3 **factorial clinical trial in Kenya.**

4 Mercy Chepkirui*^{1,2,3}, Dennis Kimego¹, Charles Nzioki⁴, Elizabeth Jowi⁵, Charles Opondo^{6,7}, Ambrose
5 Agweyu^{1,8}

6

7 1. Epidemiology and Demography Department, KEMRI-Wellcome Trust Research Programme,

8 Nairobi, Kenya

9 2. Malaria Branch, KEMRI – Centre for Global Health Research, Kisumu, Kenya

10 3. Clinical Sciences Department, Liverpool School of Tropical Medicine, Liverpool, UK

11 4. Department of Paediatrics, Machakos Level 5 County Referral Hospital, Machakos, Kenya

12 5. Department of Paediatrics, Mama Lucy Kibaki Hospital, Nairobi, Kenya

13 6. National Perinatal Epidemiology Unit, University of Oxford, UK

14 7. Department of Medical Statistics, London School of Hygiene and Tropical Medicine, UK

15 8. Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical

16 Medicine, UK

17

18 * Correspondence to: Mercy.Chepkirui@lstmed.ac.uk

19

20 Author contributions: CO conceived the project, and MC and DK developed the SMS platform. AA
21 and CO supervised the development of the application, The first draft of the manuscript was prepared
22 by MC, and further developed by AA and CO. CN and EL provided clinical trial site supervision. All
23 authors critically reviewed the paper before submission.

24 **Abstract**

25 The traditional use of sealed envelopes for randomisation is susceptible to manipulation and the risk of
26 damage to envelopes during shipping and at storage. Additionally, the filling and sealing envelopes is,
27 tedious, time-consuming, and error prone. Other randomisation alternatives such as web-based methods
28 are preferred. However, they are expensive and unsuitable in settings with poor internet infrastructure.
29 Mobile phone-based randomisation using Short Message Service (SMS) potentially offers a low-cost
30 and reliable alternative.

31 We developed an SMS-based method for random allocation of treatments. Plain text messaging or an
32 Android app were used to formulate text messages using a fixed syntax consisting of participant unique
33 identifier, trial site, stratum, and the trial name as input parameters. The system verified the input
34 parameters and obtained an allocation from the database before returning a response to the sender. The
35 text response contained the details of the treatment allocation. The study was done in two sites of a
36 multi-site 3x2 factorial clinical trial in Kenya involving two interventions with up to nine possible
37 allocations. We evaluated the accuracy of treatment allocations against the master randomisation list
38 for each randomisation SMS processed, and SMS latency in seconds. A post-implementation survey
39 was conducted to evaluate user feedback.

40 A total of 218 participants were randomised between 7th February 2022 and 11th April 2022, out of
41 which 179 were randomised to only one arm while 39 were randomised to both treatment arms.

42 Allocation accuracy was 100%. Median latency was 22 seconds with the fastest message processed in
43 10 seconds and the slowest (non-network delayed) message processed in 2129 seconds. Four users
44 completed a post-implementation survey. The pilot study demonstrated that SMS randomisation to be
45 easy, user-friendly, fast, and accurate and a feasible alternative randomisation technique.

46 **Author Summary**

47 While conducting a randomized clinical trial with a sample size of more than 4000 participants, in
48 routine care settings in Kenya, we encountered a challenge with the approach to randomisation. In our
49 study protocol we settled on the use of sealed opaque envelopes for allocation concealment. This
50 approach, given our large sample size and nine possible treatment allocations, necessitated the
51 preparation of an overwhelming (4000x9) envelope stratified across 12 study sites. This manual process
52 was tedious, time consuming and error prone, with issues arising such as mislabelling, empty
53 envelopes, and some being damaged in storage or transit.

54 Recognizing these challenges, our team was prompted to innovate an alternative digital solution, with
55 the ultimate aim of establishing a proof of concept that could support future clinical trials in routine
56 care settings. Given the high mobile penetration in Kenya, we sought to leverage SMS-based mobile
57 communication as a means of determining treatment allocation for study participants. We developed a
58 platform capable of accommodating both Android and feature phones using open-source tools. Our
59 findings indicate that SMS is a fast, user-friendly, and low-cost method, presenting a viable solution
60 that could potentially revolutionize randomisation in clinical studies. However, it is important to note
61 that our testing of this method was limited to only two study sites. Despite this, our study lays the
62 groundwork for digital randomisation and hopefully inspire future advancements in health research.

63 **Introduction**

64 Randomisation of participants in clinical trials has become the standard method of experimental control
65 aimed at reducing selection bias and eliminating confounding from known and unknown factors(1).

66 The process of randomisation generally involves two steps: (i) Generating an unpredictable sequence of
67 random assignments, and (ii) Implementing the sequence in a way that conceals the treatment assigned
68 to potential study participants until eligibility is determined(2,3). Failure to achieve proper
69 randomisation and allocation concealment may result in biased estimates of treatment effects and
70 potential loss of integrity of trial results(4).

71 Traditionally the use of sequentially numbered, opaque, sealed envelopes has been regarded an
72 acceptable method for concealing allocation of interventions in trials. However, this method is now
73 falling out of favour due to vulnerability to manipulation(5). Furthermore, sealed envelopes are
74 susceptible to damage during shipping and storage. The process of filling and sealing envelopes is also
75 a time-consuming manual process which is prone to human error, particularly in large complex studies.

76 In response to the limitations associated with sealed envelopes and recognising inadequate
77 methodological approaches in controlled trials, there is a growing inclination towards the adoption of
78 centrally administered web-based or telephone-based randomisation in large studies. However,
79 implementing these methods is challenging in settings with inadequate communication infrastructure(6)
80 and unreliable internet connectivity.

81 An alternative approach to randomisation, which is low in cost, auditable, and particularly suited for
82 Low- and Middle-Income Countries where access to mobile phone technology has rapidly
83 expanded(7,8), involves the use of mobile phone-based Short Messaging Service (SMS). SMS is a
84 method of communication that transmits text messages up to 160 characters in length, between mobile

85 devices or from a computer to a mobile device. Kenya is reported to have 98% mobile penetration
86 amongst adults(9).

87 Bulk messaging enables the synchronous delivery of SMS text messages to a vast number of recipients
88 minimizing delays and overlapping requests. In clinical trials, text messaging has proven effective in
89 reducing missed appointments(10) and has served as a cost-effective intervention for managing patients
90 with chronic illnesses(11–14).

91 We developed an SMS-based method for random allocation of treatments and subsequently undertook
92 a pilot study comparing an SMS-based randomisation platform versus the conventional approach using
93 sealed opaque envelopes. The study was conducted in parallel with a 3x2 factorial pragmatic
94 randomised controlled trial of alternative treatments for severe pneumonia among children aged 2-59
95 months(15).

96 Our aims were to evaluate the feasibility and accuracy of randomisation using text messaging by
97 estimating the response time of SMS delivery for randomisation requests, assessing the user experience
98 for envelope randomisation and SMS randomisation approaches, correct treatment allocation, and
99 determining allocation sequence concordance for envelope randomisation and SMS randomisation.

100 **Results**

101 Between February 2022 and May 2022, 218 participants were successfully randomised in the two
102 participating clinical trial sites using the SMS approach. One seventy-nine (82.1% - antibiotic arm)
103 participants were randomized in one step and 39 (17.9% - antibiotic & supportive care arm) were
104 randomized in two steps.

105 In the testing and pilot phases of the study, we logged a total of 580 SMSes, which we categorized as
106 shown in Table 1. We noted various types of SMS requests. For 151 (26%) that fell under the *'invalid*
107 *non-authorized request'* category, messages consisted of syntax completely unrelated to randomisation,
108 often missing the keyword *'randomize'*. The system reported 22 (4%) requests attempting to randomize
109 participants who were already allocated treatments. One SMS reported under the *'exhausted sequence'*
110 category was a test case scenario where the allocation sequence was no longer available for
111 randomisation. Two unregistered users made attempts to randomise participants, while 402 (69%)
112 requests had valid syntaxes that were processed, and an allocation treatment was delivered to the user
113 as a response.

Table 1: Total SMSes processed during the testing and piloting phases of the study.

Text request category	Count	Percentage (%)
Duplicate attempts	22	4
Exhausted sequence	1	0.2
Invalid non-authorized request	151	26
Non-authorized valid request	2	0.3
Valid successful randomisation	402	69
Unregistered user	2	0.3
Total	580	100

The SMS latency for the valid successful randomisation processed requests are as shown in Table 2.

The median latency was 22 seconds, with the fastest processed SMS taking just 10 seconds (IQR 29.75 seconds). *We observed one delayed response, which was eventually delivered 35 minutes later.* It stands out as an outlier as majority of the SMSes were processed under 100 seconds.

Table 2: SMS latency IQR table for valid successful randomisation requests.

Latency range	Total SMSes	Min.	1st Qu.	Median	Mean	3rd Qu	Max.
Less than 100 secs	393(98%)	10.00	16.00	21.00	31.65	44.00	96.00
All	402	10.00	16.00	22.00	46.05	45.75	2129.00

114

115 Allocation accuracy was 100% when compared to the allocation sequence.

116 Four clinicians completed a post-pilot survey. From the responses it took a clinician less than two
117 minutes to compose a randomisation text. Two exclusively used the mobile app for randomisation,
118 while two utilized both feature phones and the app. Generally, the clinicians reported that they found
119 SMS randomisation easy to grasp and use. However, opinions on preference were split; two clinicians
120 favoured envelopes, while two preferred text messaging. The Android application was notably
121 preferred over manual texting for composing the randomisation texts. A recurring challenge was
122 forgetfulness in using text randomisation.

123 **Discussion**

124 Our research provides unique insights as, to the best of our knowledge, it is the first study investigating
125 a Mobile SMS randomisation approach in a low-income setting within a complex randomized
126 controlled clinical trial. Envelope randomisation, a manual and traditional method, is reliant on the
127 integrity of filling, sealing, transporting and storage of envelopes, highlighting the need for digital
128 alternatives such as SMS. In our pilot study, we found SMS randomisation to be user-friendly,
129 efficient, fast, and accurate. It also addressed significant challenges associated with envelope
130 randomisation, such as the time-consuming process of preparing envelopes and uncertainties related to
131 envelopes being unsealed or damaged. Additionally, it eliminates the needs for paper, printing, and
132 shipping.

133 Given the high mobile penetration and widespread use of SMS messaging (16) with a the low cost of
134 SMS at \$0.0078 per unit, the potential of SMS randomisation is evident. SMS processing through a
135 local network recorded a turnaround time of 22 seconds. This highlights the approach's practical
136 potential in pragmatic trials, ensuring that there are no delays in service delivery within a busy public
137 routine care hospital setting during SMS randomisation. The introduction of the mobile application that
138 automated SMS formulation made randomisation more efficient, and no internet connectivity was
139 needed. Despite the predominance of feature phones in the Kenyan Market(17), our solution
140 demonstrates versatility, proving that mobile applications and feature phones can be seamlessly
141 integrated and used interchangeably for SMS randomisation. This ensures broad accessibility and
142 efficiency across different device types.

143

144

145 **Digital randomisation techniques**

146 As randomisation is a key determinant of the effectiveness of a clinical trial, trialists need to embrace
147 improved and innovative methodologies that include the use of technology where applicable. Trialists
148 are increasingly exploring digital options for conducting randomised controlled trials to mitigate
149 challenges affecting recruitment in clinical trials(18–20). Digitization stands out in ensuring correct and
150 accurate treatment allocation. This not only helps in maintaining the integrity of the clinical trial but
151 also plays a crucial role in minimizing and scrutinizing potential biases in trial outcomes, thereby
152 enhancing the credibility of the results. Clinical trial monitoring becomes more efficient as trial
153 progress can be readily traced in real-time through a randomisation dashboard integrated into the trial
154 data collection process. This feature is particularly beneficial for adaptive clinical trial designs, where
155 the ability to make data-driven decisions in real-time is paramount(21).

156 **Clinical trials in low-resource settings**

157 Mobile-based randomisation can solve a number of clinical trial challenges inherent in low- resource
158 settings such as financial constraints, operational barriers such as remote locations of study sites, and
159 limited human capital (22). Setting up clinical trials with complex designs can be prohibitively
160 expensive in such settings (23). This calls for effective methods of conducting trials that deliver
161 credible results while minimizing cost. Our approach, developed using open-source tools, serves a
162 testament to the feasibility of digitizing clinical trial methods in low resource settings. Representing
163 marginalised populations in health research and innovation is crucial for addressing the significant
164 disease burden in low-income countries in a fair and equitable manner (22,24–26). There is an urgent

165 need for investment in solutions that will increased the number of clinical trials conducted in low-
166 income countries (27). As our approach only targets two components of clinical trials – randomisation
167 and trial monitoring – additional research is required to pilot other low-cost tools that could improve
168 the quality of clinical trials in similar contexts.

169 **Limitations and recommendations**

170 We acknowledge various limitations to our study. The pilot was done in a restricted context with
171 limited number of users and trial sites. Users were clinicians already involved in the larger randomized
172 controlled trial, which could have influenced their feedback and experience. There may be learning
173 curve or initial hesitations for naïve. Clinicians admitting to often forgetting to send the text request
174 after opening the envelope also highlights a behavioural aspect that could be addressed in future
175 implementations to ensure consistent use of the system. The application logic was informed by a simple
176 randomisation technique and tested in an urban setting in Kenya setting with local SMS service
177 providers. This paper does not extend the discussion to implementation in other countries or in rural
178 Kenya where network connectivity may be unstable. Nonetheless, our findings are promising and
179 recommend conducting pilots in various settings, clinical trial designs, and geographical locations.
180 Future iterations of the SMS-based system could introduce enhancements that optimize reliability and
181 guarantee integrity.

182 **Conclusions**

183 The promising results from our pilot indicate that there is potential for wider implementation in large-
184 scale clinical trials. The observed improvements in efficiency, high accuracy, and user acceptance point
185 to the viability of SMS randomisation in clinical research in both low and high resource settings. We

186 used open-source tools for the development and testing of the SMS platform, ensuring accessibility for
187 further development and improvements. This lessons from this trial serve as a reference point for future
188 low-cost technology-driven innovations to expand the reach and quality of clinical trials globally.

189 **Materials and methods**

190 We conducted a prospective two-arm pilot study nested within an actively recruiting randomised
191 controlled trial. This study was conducted in two phases. The development phase (Phase 1) involved
192 the design specification of the SMS platform, and initial testing in web-based, text messaging and
193 Android applications. The implementation phase (Phase 2) involved deployment of the application at
194 two public hospitals in Kenya: Machakos Level 5, and Mama Lucy Kibaki Hospitals, selected
195 purposively from a pool of 12 clinical trial sites due to their high participant recruitment rates.

196 **Phase 1: Development phase**

197 We designed and developed a three-tier SMS-based randomisation system consisting of data,
198 application, and presentation interfaces (Figure 1). The requirements of the application were derived
199 from standard operating procedures for randomisation in the larger clinical trial. Therefore, the logic
200 was structured to accommodate a multi-step factorial randomisation design involving two interventions
201 with up to nine possible allocations (Figure 2).

Figure 1: SMS platform design framework. The data tier stored all the system data, the business logic tier processed all the system transactions, and the presentation tier was the point of interaction between the user and the system.

202

Figure 2: Factorial allocation of treatments. Three antibiotic treatment arms (crystalline penicillin & gentamicin, ceftriaxone, and Intravenous (IV) amoxicillin-clavulanic acid) and two supportive care treatment arms (Nasogastric feeds and IV fluids).

203 Each message consisted of a predefined ordered syntax comprising the participant unique identifier,
 204 trial site, stratum, and trial name. Detailed descriptions of the syntax, message scenarios, and expected
 205 responses are provided in Table 3 and Table 4.

Table 3: SMS formulation syntax of a randomisation request.

Type of message	Input parameters formats	Example text
A request to randomise a participant in each stratum at a trial site in a multisite clinical trial.	Randomise [IPNO] to [study name] [sitename] [stratum name]	<i>{Randomise RL567 to SEARCH MKSRT supportive}</i> RL567 – IPNO ¹ SEARCH – Study name MKSRT – Site name Supportive – stratum
A request to randomise a participant in each site (not stratified) in a multisite clinical trial	Randomise [IPNO] to [Study name] [sitename]	<i>{Randomise KL789 to SEARCH MMLY}</i> KL789 – IPNO SEARCH – study name MMLY – site name

¹ The unique patient identifier primarily assigned to a patient at the public hospital.

Table 4: Various SMS formulation request scenarios and their respective expected responses.

Event scenario	Expected response
Non-registered user	<i>The number [phone number] does not belong to an active user who is authorised to randomise participants study at [site name]. Contact [administrator contact] for more details.</i>
Exhausted allocation list	<i>Random allocations to the [study name] study is no longer available. Please contact the study co-ordination centre [Phone number].</i>
Invalid message format	<i>Incorrect message format; use: randomise [IPNO] to [studyID] [siteID] or: randomise [IPNO] to [studyID] [siteID] [phoneNO] without the straight brackets. You may also add your phone number at the end of the message if using an authorised phone that does not belong to you.</i>
An attempt to randomise a participant twice	<i>The participant with the [IPNO] is already allocated [allocation] by [username] at [timestamp].</i>
An attempt to deactivate non-existing user	<i>Deactivation failed; there is no record with the phone number [phone number] in the list of users.</i>
Successful user deactivation	<i>The user with the phone number [phone number], is now an inactive user.</i>

Successful user registration	<i>[Username] phone number [phone number], has been added to the list of users authorised to randomise participants to the [study name] study at the [site name] site.</i>
Delete user	<i>The phone number [phone number], has been removed from the list of users.</i>
An attempt to add user twice	<i>[username], phone number [phone number], already exists in the list of users.</i>
Successful randomisation	<i>Participant [IPNO] has been randomised to [allocation] in the [study name] study. The unique number for the participant is [participant randomisation ID]. Randomised by [trial staff name] on [timestamp].</i>

206

207 The application tier verified the input parameters received from the mobile network operator through
208 SMS or HTTP via a Representational State Transfer Application Programming Interface (REST API),
209 obtaining an allocation from the data tier stored on a local database. It then returned a response to the
210 sender through an SMS. The text response contained details of the treatment allocation, participant
211 identifier, and identity of the study staff undertaking randomisation. The system was designed to
212 identify duplicate randomisation attempts using unique patient identifiers (IPNO).

213

214 The randomisation application logged all the SMS processed (Table 5). These included invalid text
215 messages, duplicated attempts to randomise, non-authorized request from users not registered and
216 successfully processed valid randomisation requests. Valid randomisation and allocations were logged

217 and captured in the administrative dashboard for review during trial monitoring. This log captured
218 allocations for the two clinical trial arms – *antibiotic care and supportive care*. Antibiotic treatment
219 allocation was the first step of randomisation consisting of three antibiotic regimens: crystalline
220 penicillin and gentamicin, ceftriaxone, and intravenous (IV) amoxicillin-clavulanic acid. Supportive
221 care arm was allocated as the second randomisation step consisting of two treatments: Nasogastric
222 (NG) feeds and IV fluids (Figure 2).

Table 5: SMS requests categories.

No.	Category	Definition
1	Duplicate attempts	A SMS request that attempted to randomize a participant who had already been allocated a treatment in any arm.
2	Exhausted sequence	An attempt to randomize when an allocation sequence had been exhausted or fully utilized.
3	Invalid non-authorized request	A non-authorized user attempted to randomize a participant by sending a non-structured SMS.
4	Non-authorized valid request	A non-authorized user attempted to randomize a participant by sending a correctly structured SMS.
5	Valid successful randomisation	A randomisation attempt that was processed and a treatment allocation was sent out as a response to the user.

6	Unregistered user	A user who had not been registered attempts to randomize a participant.
---	-------------------	---

223

224 The administrative dashboard was a central hub for monitoring all transactions and randomisation logs.

225 It stored the randomisation sequence, which was uploaded, during set up allowed administrators to

226 supervise trial randomisation, manage users, and track recruitment across different sites and strata. A

227 feature phone and the mobile application served as randomisation access points.

228

229 The mobile application was developed in Java for Android, and the web-based platform was developed

230 using the PHP Laravel framework. The platform integrated with an SMS Application Programming

231 Interface (API) from a local premium rate service provider (PRSP). One local mobile network operator

232 was chosen for piloting due to cost related estimations. The source code for the SMS dashboard and

233 the mobile application of this project is archived on GitHub (28,29). The web-based administrative

234 dashboard is locally hosted on the KEMRI-Wellcome Trust servers following data management

235 procedures outlined in the study protocol. At the time of development of this manuscript, the mobile

236 application had not yet been published on the Google Play Store.

237 **Phase 2: Pilot SMS randomisation**

238 Four clinical trial clinicians carried out the SMS randomisation pilot, with 2 clinicians stationed at each

239 trial site. All users underwent training on how to use the SMS randomisation prior to piloting. The

240 SMS platform was implemented in two modes: through text messaging on feature phones and

241 smartphones using an Android mobile application. SMS randomisation was conducted alongside the
242 traditional method of using envelopes. Each clinician was provided with a tablet computer with SIM
243 card registered to the study. The custom Android application was installed on each of the tablets with
244 each clinician having a separate account with a designated role to randomise participants. All system
245 users were pre-registered in the database.

246

247 A study clinician would first screen patients for eligibility and then proceed to randomise them using
248 sealed envelopes (the primary method) and finally repeat the process using text messaging.

249 Randomisation requests were submitted in structured text format, either manually typed in the phone's
250 default text messaging application or formulated automatically by the Android application. Texts from
251 the Android app included a phone number at the end, while manually typed texts did not.

252 Randomisation marked the final step in recruitment before a treatment was allocated to a participant.

253 Treatment allocation and administration was based on the envelope concealment method.

254

255 Patient care was always the priority, ensuring that the study procedures did not delay or interfere with
256 treatment. There was no direct risk to participants from the procedures of this study. If technical issues
257 arose, the clinicians were able to call the user support team at the KEMRI-Wellcome Trust Programme
258 for help. Additionally, weekly review meetings were held to assess progress and address any emerging
259 challenges. A post-implementation survey was used to evaluate user feedback. We built a user
260 feedback into the mobile application, which only became active after the pilot implementation was
261 completed. Each user of the randomisation module completed the questionnaire. The study covered the

262 cost of the premium SMS subscription package, ensuring that users did not incur any additional
263 charges.

264 **Data analysis**

265 The SMS platform logged data for each SMS request made, capturing both the initiation time of the
266 request and the time a response was delivered to the user. This enabled us to calculate a turnaround
267 time, or SMS latency, in seconds for each processed message. We then analysed the data by computing
268 the medians with interquartile ranges (IQRs) for turnaround time in seconds. To better describe the
269 range of SMS requests made, we grouped all requests into 6 distinct categories with each SMS
270 assigned to a group (Table 5). We only computed the SMS latency for valid randomisation requests
271 (group 5 in Table 5). A valid request was defined as by the correct structured syntax with all the input
272 parameters required for randomisation.

273 To determine the validity of an (In-Patient Number) (IPNO), we extracted all IPNOs in each SMS
274 request and compared them against the IPNOs in the clinical trial database. We evaluated the accuracy
275 of treatment allocations by comparing SMS request response for treatment allocation with the master
276 randomisation list for each processed message. Survey responses from all the users were reviewed and
277 summarized.

278

279 **Acknowledgments**

280 This project would not have been possible without the kind of support and help from many individuals.
281 We would like to extend our sincere gratitude to the following partner: SEARCH Clinical Trial
282 Management Group, Mama Lucy Kibaki Hospital study clinicians, paediatric team, and data clerks,

283 Machakos Level 5 Hospital study clinicians, paediatric team, and data clerks, and the KEMRI –
284 Wellcome Trust Operations Department.

285 **Ethics approval and consent to participate**

286 The Kenya Medical Research Institute (KEMRI) Scientific and Ethics Review Unit approved the
287 collection of the deidentified data analysed in this study. The study clinicians consented to participate
288 in the SMS randomisation pilot and to use their names and email addresses for SMS notification and
289 verification purposes.

290 **Availability of data and materials**

291 The data utilized in this work was generated from the SMS randomisation system. Further access to the
292 data and additional system design materials can be sought through a request to KEMRI Wellcome
293 Trust Research Programme’s Data Governance Committee through email: dgc@kemri-wellcome.org.

294 **Competing interests**

295 The authors declare that they have no competing interests.

296 **Funding**

297 The research reported was funded through The Global Health Network methodology hub and the
298 MRC-NIHR Trials Methodology Research Partnership (TMRP) - TMRP reference number GH/182.

299 **References**

- 300 1. Altman DG. A fair trial? *BMJ*. 1984 Aug 11;289(6441):336–7.
- 301 2. Dettori J. The random allocation process: two things you need to know. *Evid-Based Spine-Care J*.
302 2010 Dec;1(3):7–9.

- 303 3. Kim J, Shin W. How to Do Random Allocation (Randomization). *Clin Orthop Surg*. 2014
304 Mar;6(1):103–9.
- 305 4. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of
306 randomised trials affect estimates of intervention efficacy reported in meta-analyses? *The Lancet*.
307 1998 Aug 22;352(9128):609–13.
- 308 5. Kennedy ADM, Torgerson DJ, Campbell MK, Grant AM. Subversion of allocation concealment in
309 a randomised controlled trial: a historical case study. *Trials*. 2017 May 2;18(1):204.
- 310 6. Quaglio G, Dario C, Karapiperis T, delponte L, McCormack S, Tomson G, et al. Information and
311 communications technologies in low and middle-income countries: survey results on economic
312 development and health (Part I). *Health Policy Technol*. 2016 Jul 1;
- 313 7. Aker JC, Mbiti IM. Mobile Phones and Economic Development in Africa. *J Econ Perspect*. 2010
314 Sep;24(3):207–32.
- 315 8. Aranda-Jan CB, Mohutsiwa-Dibe N, Loukanova S. Systematic review on what works, what does
316 not work and why of implementation of mobile health (mHealth) projects in Africa. *BMC Public*
317 *Health*. 2014 Feb 21;14(1):188.
- 318 9. Kharono B, Kaggiah A, Mugo C, Seeh D, Guthrie BL, Moreno M, et al. Mobile technology access
319 and use among youth in Nairobi, Kenya: implications for mobile health intervention design.
320 *mHealth*. 2022 Jan;8:7–7.
- 321 10. Junod Perron N, Dao MD, Righini NC, Humair JP, Broers B, Narring F, et al. Text-messaging
322 versus telephone reminders to reduce missed appointments in an academic primary care clinic: a
323 randomized controlled trial. *BMC Health Serv Res*. 2013 Apr 4;13:125.
- 324 11. Chen Z wen, Fang L zheng, Chen L ying, Dai H lei. Comparison of an SMS text messaging and
325 phone reminder to improve attendance at a health promotion center: A randomized controlled trial.
326 *J Zhejiang Univ Sci B*. 2008 Jan;9(1):34–8.
- 327 12. Finitis DJ, Pellowski JA, Johnson BT. Text message intervention designs to promote adherence to
328 antiretroviral therapy (ART): a meta-analysis of randomized controlled trials. *PloS One*.
329 2014;9(2):e88166.
- 330 13. Park LG, Howie-Esquivel J, Chung ML, Dracup K. A text messaging intervention to promote
331 medication adherence for patients with coronary heart disease: a randomized controlled trial.
332 *Patient Educ Couns*. 2014 Feb;94(2):261–8.
- 333 14. Thakkar J, Kurup R, Laba TL, Santo K, Thiagalingam A, Rodgers A, et al. Mobile Telephone Text
334 Messaging for Medication Adherence in Chronic Disease: A Meta-analysis. *JAMA Intern Med*.
335 2016 Mar;176(3):340–9.

- 336 15. Agweyu A. Supportive Care and Antibiotics for Severe Pneumonia Among Hospitalized Children
337 [Internet]. clinicaltrials.gov; 2020 Nov [cited 2021 Aug 15]. Report No.: NCT04041791. Available
338 from: <https://clinicaltrials.gov/ct2/show/NCT04041791>
- 339 16. Sector Statistics Report Q3 2022-2023.pdf [Internet]. [cited 2023 Sep 13]. Available from:
340 <https://www.ca.go.ke/sites/default/files/2023-06/Sector%20Statistics%20Report%20Q3%202022->
341 [2023.pdf](https://www.ca.go.ke/sites/default/files/2023-06/Sector%20Statistics%20Report%20Q3%202022-2023.pdf)
- 342 17. Feature phones still dominate Kenya’s handset market in a smartphone age | Business News Africa
343 [Internet]. Financial Fortune Media. 2023 [cited 2023 Sep 13]. Available from:
344 [https://www.financialfortunemedia.com/feature-phones-still-dominate-kenyas-handset-market-in-](https://www.financialfortunemedia.com/feature-phones-still-dominate-kenyas-handset-market-in-the-smartphone-age/)
345 [the-smartphone-age/](https://www.financialfortunemedia.com/feature-phones-still-dominate-kenyas-handset-market-in-the-smartphone-age/)
- 346 18. Blatch-Jones A, Nuttall J, Bull A, Worswick L, Mullee M, Peveler R, et al. Using digital tools in
347 the recruitment and retention in randomised controlled trials: survey of UK Clinical Trial Units and
348 a qualitative study. *Trials*. 2020 Dec;21(1):304.
- 349 19. Mehaffey L. RingCentral. 2021 [cited 2023 Sep 13]. 5 best recruitment strategies for clinical trials.
350 Available from: [https://www.ringcentral.com/us/en/blog/5-best-recruitment-strategies-for-clinical-](https://www.ringcentral.com/us/en/blog/5-best-recruitment-strategies-for-clinical-trials/)
351 [trials/](https://www.ringcentral.com/us/en/blog/5-best-recruitment-strategies-for-clinical-trials/)
- 352 20. Raven-Gregg T, Wood F, Shepherd V. Effectiveness of participant recruitment strategies for
353 critical care trials: A systematic review and narrative synthesis. *Clin Trials*. 2021 Aug;18(4):436–
354 48.
- 355 21. Lauffenburger JC, Choudhry NK, Russo M, Glynn RJ, Ventz S, Trippa L. Designing and
356 conducting adaptive trials to evaluate interventions in health services and implementation research:
357 practical considerations. *BMJ Med*. 2022 Jul;1(1):e000158.
- 358 22. Alemayehu C, Mitchell G, Nikles J. Barriers for conducting clinical trials in developing countries-
359 a systematic review. *Int J Equity Health*. 2018 Dec;17(1):37.
- 360 23. Erber AC, Ewing V, Turner M, Molla M, Murbe G, Enquoselassie F, et al. Setting up a pragmatic
361 clinical trial in a low-resource setting: A qualitative assessment of GoLBeT, a trial of podoconiosis
362 management in Northern Ethiopia. Ramos AN, editor. *PLoS Negl Trop Dis*. 2021 Jul
363 28;15(7):e0009582.
- 364 24. Lang T, Siribaddana S. Clinical Trials Have Gone Global: Is This a Good Thing? *PLoS Med*. 2012
365 Jun 12;9(6):e1001228.
- 366 25. Boutayeb A. The Burden of Communicable and Non-Communicable Diseases in Developing
367 Countries. In: Preedy VR, Watson RR, editors. *Handbook of Disease Burdens and Quality of Life*
368 *Measures* [Internet]. New York, NY: Springer New York; 2010 [cited 2023 Sep 13]. p. 531–46.
369 Available from: http://link.springer.com/10.1007/978-0-387-78665-0_32

- 370 26. Rottingen JA, Chamas C, Goyal L, Harb H, Lagrada L, Mayosi B. Securing the public good of
371 health research and development for developing countries. Bull World Health Organ. 2012 May
372 1;90(5):398–400.
- 373 27. Barriers to Conducting Clinical Trials in Developing Countries - PMC [Internet]. [cited 2023 Sep
374 13]. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6928677/>
- 375 28. Muoki D. muokid3/prisms_mobi [Internet]. 2023 [cited 2023 Sep 13]. Available from:
376 https://github.com/muokid3/prisms_mobi
- 377 29. Muoki D. muokid3/prisms [Internet]. 2023 [cited 2023 Sep 13]. Available from:
378 <https://github.com/muokid3/prisms>

379

380 **Supporting information**

381

382 **S1 Fig. SMS platform design framework.**

383 The data tier stored all the system data, the business logic tier processed all the system transactions, and
384 the presentation tier was the point of interaction between the user and the system.

385 **S2 Fig. Factorial allocation of treatments.**

386 Three antibiotic treatment arms (crystalline penicillin & gentamicin, ceftriaxone, and Intravenous (IV)
387 amoxicillin-clavulanic acid) and two supportive care treatment arms (Nasogastric feeds and IV fluids).


388 **S1 Table. Total SMSes processed during the testing and piloting phases of the study.**

389 **S2 Table. SMS latency IQR table for valid successful randomisation requests.**

390 **S3 Table. SMS formulation syntax of a randomisation request.**

391 **S4 Table. Various SMS formulation request scenarios and their respective expected responses.**

392 **S5 Table. SMS requests categories.**



S1 Fig

